Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

Gynecologic Oncology

Volumn 109, Issue 2, 2008, Pages 174-181

  Alberts, David S ^a   Marth, Christian ^b   Alvarez, Ronald D ^c   Johnson, Gary ^d   Bidzinski, Mariusz ^e   Kardatzke, David R ^f   Bradford, Williamson Z ^f   Loutit, Jeff ^f   Kirn, David H ^f   Clouser, Mary C ^a   Markman, Maurie ^g  

^a UNIVERSITY OF ARIZONA   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e Klinika Nowotworów Narza dów P ciowych Kobiecych   (Poland)

^f InterMune Inc   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Advanced ovarian; Carboplatin; First line treatment; Interferon 1b; Paclitaxil; Primary peritoneal carcinomas

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GAMMA1B INTERFERON; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASCITES; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHEMOSENSITIZATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOKALEMIA; IMMUNOSTIMULATION; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SMALL INTESTINE OBSTRUCTION; SURVIVAL TIME; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-GAMMA, RECOMBINANT; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 42749083267     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.01.005     Document Type: Article

References (29)

1. Jamal, A, et al. Cancer Statistics 2007. CA Cancer J Clin Jan-Feb 57(1):43-66
2. McGuire. WP. Epithelial ovarian cancer. ASCO 2000 Educational Book 2000;541-6.
3. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
4. du Bois A., Luck H.J., Meier W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 95 (2003) 1320-1329
5. Berek J.S., Schultes B.C., and Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21 (2003) 168-174
6. Barton C., Davies D., Balkwill F., et al. Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer 41 (2005) 1474-1486
7. Nehme A., Julia A.M., Jozan S., et al. Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell lines. Eur J Cancer 30A (1994) 520-525
8. Marth C., Zeimet A.G., Herold M., et al. Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67 (1996) 826-830
9. Welander C.E., Homesley H.D., Reich S.D., et al. A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol 11 (1988) 465-469
10. Pujade-Lauraine E., Guastalla J.P., Colombo N., et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 14 (1996) 343-350
11. Windbichler G.H., Hausmainger H., Stummvoll W., et al. Interferon gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82 (2000) 1138-1144
12. Chu C.S., Menzin A.W., Leonard D.G.V., et al. Primary peritoneal carcinoma: a review of the literature. Obstet Gynecol Surv 543 (1999) 3234-3335
13. Marth C., Windbichler G.H., Hausmaninger H., et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer 16 (2006) 1522-1528
14. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 92 (2000) 205-216
15. DeMets D., and Lan K. Interim analysis: the alpha spending function approach. Stat Med 13 (1994) 1341-1352
16. Fleming T., Harrington D., and O'Brien P. Designs for group sequential tests. Control Clin Trials 13 (1984) 348-361
17. Marth C., Fiegl H., Zeimet A.G., et al. Interferon-γ expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 191 (2004) 1598-1606
18. Welander C.E. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs. Cancer 59 (1987) 617-619
19. + T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171 (2003) 5931-5939
20. + helper T cell responses in cancer patients. Blood 106 (2005) 1008-1011
21. + regulatory T cells. J Immunol 174 (2005) 90-98
22. Steitz J., Bruck J., Lenz J., et al. Depletion of CD25 (+) CD4 (+) T cells and treatment with tyrosine-related protein 2-transduced dendritic cells enhance the interferon α-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 61 (2001) 8643-8646
23. Uyttenhove C., Pilotte L., Theate I., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 9 (2003) 1269-1274
24. Marth C., Weger A., Muller-Holzner E., et al. The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 29A (1993) 1863-1868
25. Barnett B., Kryczek I., Cheng P., et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54 (2005) 369-377
26. Wolf D., Wolf A.M., Rumpold H., et al. The expression of the regulatory T Cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11 (2005) 8326-8331
27. Wood K.J., and Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol 27 (2006) 183-187
28. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
29. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032